Tabula Rasa HealthCare (TRHC) Reports Q4 EPS of $0.09, Beats on Revenues

Note: EPS may not be comparable

Tabula Rasa HealthCare (NASDAQ: TRHC) reported Q4 EPS of $0.09, versus $0.17 reported last year. Revenue for the quarter came in at $43.9 million versus the consensus estimate of $38.85 million.

• Non-GAAP Adjusted net income per diluted share was $0.09, compared to Non-GAAP Adjusted net income per diluted share of $0.10.
• Total revenue was $43.9 million, an increase of 60.9%.

Financial Outlook

First Quarter 2018 Guidance: Revenue for TRHC’s first quarter 2018 is expected to be in the range of $42 million to $43 million. Net loss is expected to be in the range of $1.4 million to $1.9 million. Adjusted EBITDA is expected to be in the range of $4.0 million to $4.5 million. The first quarter guidance is reflective of the seasonality of the SinfoníaRx business, which generally has a lighter first quarter as the business qualifies the members that will be eligible to receive a medication therapy management benefit.

Full Year 2018 Guidance: Revenue for fiscal year 2018 is expected to be in the range of $185 million to $195 million. TRHC expects net income in the range of $2.4 million to $6.4 million. The net income projection for 2018 does not include any tax effects related to the vesting of restricted stock issued at the time of the initial public offering in the second quarter, the amount will be dependent upon TRHC’s stock price on May 31, 2018. Adjusted EBITDA is expected to be in the range of $28.0 million to $32.0 million.

For earnings history and earnings-related data on Tabula Rasa HealthCare (TRHC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c